Mathew Cherian

1.4k total citations
64 papers, 794 citations indexed

About

Mathew Cherian is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Mathew Cherian has authored 64 papers receiving a total of 794 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 25 papers in Pulmonary and Respiratory Medicine and 15 papers in Cancer Research. Recurrent topics in Mathew Cherian's work include HER2/EGFR in Cancer Research (16 papers), Advanced Breast Cancer Therapies (16 papers) and Breast Cancer Treatment Studies (14 papers). Mathew Cherian is often cited by papers focused on HER2/EGFR in Cancer Research (16 papers), Advanced Breast Cancer Therapies (16 papers) and Breast Cancer Treatment Studies (14 papers). Mathew Cherian collaborates with scholars based in United States, India and Australia. Mathew Cherian's co-authors include Bhuvaneswari Ramaswamy, Robert Wesolowski, Priyanka Bhateja, Sarmila Majumder, Mahmoud Kassem, Sagar Sardesai, William E. Carson, Daniel G. Stover, Maryam B. Lustberg and Dionisia Quiroga and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Mathew Cherian

55 papers receiving 772 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mathew Cherian United States 15 321 220 182 151 131 64 794
Kosuke Yamaguchi Japan 14 365 1.1× 346 1.6× 207 1.1× 148 1.0× 56 0.4× 50 879
Zhen Xiang China 15 266 0.8× 467 2.1× 156 0.9× 201 1.3× 299 2.3× 28 1.1k
Zhaoyang Wang China 18 262 0.8× 562 2.6× 116 0.6× 140 0.9× 140 1.1× 61 1.1k
Giorgia Mandili Italy 19 202 0.6× 484 2.2× 96 0.5× 105 0.7× 144 1.1× 41 992
Silvia Boffo United States 14 176 0.5× 323 1.5× 102 0.6× 57 0.4× 79 0.6× 30 612
Qiang Du China 19 156 0.5× 377 1.7× 73 0.4× 152 1.0× 149 1.1× 36 889
Patrick P. Koty United States 15 144 0.4× 416 1.9× 189 1.0× 141 0.9× 105 0.8× 29 930

Countries citing papers authored by Mathew Cherian

Since Specialization
Citations

This map shows the geographic impact of Mathew Cherian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mathew Cherian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mathew Cherian more than expected).

Fields of papers citing papers by Mathew Cherian

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mathew Cherian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mathew Cherian. The network helps show where Mathew Cherian may publish in the future.

Co-authorship network of co-authors of Mathew Cherian

This figure shows the co-authorship network connecting the top 25 collaborators of Mathew Cherian. A scholar is included among the top collaborators of Mathew Cherian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mathew Cherian. Mathew Cherian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Datta, Jharna, Ramesh K. Ganju, William E. Carson, et al.. (2025). Sulfatase 2 inhibition sensitizes triple-negative breast cancer cells to paclitaxel through augmentation of extracellular ATP. Cancer Biology & Therapy. 26(1). 2483989–2483989. 1 indexed citations
2.
3.
Raghavendra, Akshara Singareeka, Qingchun Jin, Melissa Grimm, et al.. (2024). Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status☆. ESMO Open. 9(11). 103973–103973. 4 indexed citations
4.
Sukumar, Jasmine, Sagar Sardesai, Ai Ni, et al.. (2024). Real‐world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer. Cancer Medicine. 13(12). e7317–e7317.
5.
Goldstein, Daniel A., Dionisia Quiroga, Mahmoud Kassem, et al.. (2023). The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer. Oncology and Therapy. 11(3). 361–374. 1 indexed citations
6.
Madison, Annelise A., Rebecca Andridge, Megan E. Renna, et al.. (2023). Inflamed but not impulsive: Acute inflammatory cytokine response does not impact prepotent response inhibition. Journal of Affective Disorders. 342. 1–9. 3 indexed citations
7.
Renna, Megan E., Annelise A. Madison, Juan Peng, et al.. (2023). Worry and Mindfulness Differentially Impact Symptom Burden Following Treatment Among Breast Cancer Survivors: Findings From a Randomized Crossover Trial. PubMed Central. 1 indexed citations
8.
Madison, Annelise A., Megan E. Renna, Rebecca Andridge, et al.. (2023). Conflicts hurt: social stress predicts elevated pain and sadness after mild inflammatory increases. Pain. 164(9). 1985–1994. 5 indexed citations
9.
Sukumar, Jasmine, Sagar Sardesai, Ai Ni, et al.. (2023). Abstract P1-02-03: Real World Treatment Patterns of Adjuvant Endocrine Therapy and Ovarian Suppression in Premenopausal HR+/HER2+ Breast Cancer. Cancer Research. 83(5_Supplement). P1–2. 1 indexed citations
10.
Damodaran, Senthil, Ciara C. O’Sullivan, Ahmed Elkhanany, et al.. (2023). Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2− breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2. Annals of Oncology. 34(12). 1131–1140. 25 indexed citations
11.
12.
Grimm, Michael, Jasmine Sukumar, Patrick Schnell, et al.. (2023). Survival outcomes seen with neoadjuvant chemotherapy in the management of locally advanced inflammatory breast cancer (IBC) versus matched controls. The Breast. 72. 103591–103591. 4 indexed citations
13.
Krishnamurthy, Jairam, Jingqin Luo, Rama Suresh, et al.. (2022). A phase II trial of an alternative schedule of palbociclib and embedded serum TK1 analysis. npj Breast Cancer. 8(1). 35–35. 5 indexed citations
14.
Ing, Steven, et al.. (2021). Osteopetrosis, a potential mimicker of sclerotic metastatic bone lesions in breast cancer. SHILAP Revista de lepidopterología. 3. 100056–100056. 1 indexed citations
15.
Benner, Brooke, Dionisia Quiroga, Thomas E Schultz, et al.. (2020). <p>Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development</p>. Drug Design Development and Therapy. Volume 14. 1693–1704. 121 indexed citations
16.
Sardesai, Sagar, Mohamed Badawi, Ewa Mrózek, et al.. (2020). A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer. Investigational New Drugs. 38(5). 1400–1410. 24 indexed citations
17.
Stover, Daniel G., Robert Wesolowski, Sagar Sardesai, et al.. (2020). Assessment of outcomes and novel immune biomarkers in metaplastic breast cancer: a single institution retrospective study. World Journal of Surgical Oncology. 18(1). 11–11. 18 indexed citations
18.
Kassem, Mahmoud, Gary Tozbikian, Julia White, et al.. (2020). TTF-1 Positive Primary Small Cell Carcinoma of the Breast: A Case Report and Review of the Literature. Frontiers in Endocrinology. 11. 228–228. 12 indexed citations
19.
Sardesai, Sagar, Jasmine Sukumar, Mahmoud Kassem, et al.. (2020). Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer. Cardio-Oncology. 6(1). 26–26. 22 indexed citations
20.
Cherian, Mathew, Raoul Tibes, Feng Gao, et al.. (2016). A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndrome. Leukemia & lymphoma. 57(11). 2535–2540. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kosuke Yamaguchi Breakdown of academic impact, for papers by Zhen Xiang Breakdown of academic impact, for papers by Zhaoyang Wang Breakdown of academic impact, for papers by Giorgia Mandili Breakdown of academic impact, for papers by Silvia Boffo Breakdown of academic impact, for papers by Qiang Du Breakdown of academic impact, for papers by Patrick P. Koty
Rankless by CCL
2026